Youniqor
phase 1consumer product · high · Thu Feb 12 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate and develop a next-generation nutritional formulation intended to support mitochondrial and cellular function and address biological drivers of aging to extend healthspan.
Daily dietary supplement intervention; Safe-Age clinical trial evaluates safety and tolerability in healthy adults aged 60 to 80 over 8 weeks using adverse event monitoring, vital signs, laboratory parameters, urine tests, and electrocardiograms.
Safe-Age Study listed as enrolling to evaluate safety and tolerability of Youniqor in healthy older adults; YOXLO was also selected as a 2025 XPRIZE Healthspan semi-finalist and received milestone funding.
Company states preclinical results are promising; no detailed clinical efficacy or safety results are provided in the supplied material.
NLRP3 and auto-aging healthspan research
exploratoryresearch program · medium · Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Investigate NLRP3 as a central upstream driver of inflammation, senescence, accelerated aging, and exceptional healthspan, and frame healthspan-focused geroscience around manifest aging and functional decline.
Scientific review and viewpoint research synthesizing evidence on NLRP3 targeting, healthy centenarians, GlyNAC, NLRP3 inhibition, CaAKG, frailty, and real-world aging models.
YOXLO-affiliated publication in Ageing Research Reviews arguing for phenotype-driven healthspan studies alongside rigorous lifespan testing; earlier Frontiers in Aging review proposed the auto-aging framing around NLRP3.
The supplied abstracts report that NLRP3 targeting is associated in cited studies with healthspan-like phenotypes in mice, extended healthspan in monkeys, and reversal of aging symptoms in humans; the 2025 viewpoint argues that interventions such as GlyNAC, NLRP3 inhibition, and CaAKG show translationally meaningful functional benefits in real-world aging models.
NLRP3 healthspan and auto-aging research program
exploratoryresearch program · medium · Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Investigate NLRP3 as a central driver of aging-related inflammation, cellular senescence, and shortened healthspan, using healthy centenarians as a model for exceptional healthspan and proposing NLRP3 targeting as a strategy to extend healthspan.
Literature-based geroscience research and conceptual framework development focused on NLRP3, healthy centenarian genetics, low-grade inflammation, cellular senescence, and real-world aging models.
Publication of YOXLO-affiliated geroscience work arguing for phenotype-driven healthspan studies alongside lifespan testing and discussing interventions such as NLRP3 inhibition.
The supplied review states that NLRP3 targeting produces healthy-centenarian-like phenotypes in mice, extends healthspan in monkeys, and reverses aging symptoms in humans, but these are literature claims rather than YOXLO-generated product results in the supplied material.
Function-first healthy aging research program
exploratoryresearch program · medium · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Build science-based tools, products, and research programs to help people understand and preserve functional reserve as they age.
Company research and product-development program centered on functional reserve and healthy aging; supplied materials mention formulation transparency, independent quality testing, and participation in healthspan-focused competition activity but do not disclose a complete protocol.
Selected as a 2025 Semi-Finalist in the XPRIZE Healthspan competition.
Stay Younger for Longer healthy aging program
undisclosedresearch program · low
Help more people remain active and independent into their nineties by slowing aging with science-based interventions and prolonging good health as people age.
Patented research into science-based interventions for healthy aging; specific intervention, assay, or trial details are not disclosed in the supplied material.
YOXLO is inviting people to join its mission and request a Founding Member information package.
YOXLO Reserve
exploratorybiomarker · medium
Emerging measurement direction focused on assessing functional reserve, including strength, clarity, and resilience, as part of YOXLO's function-first healthy-aging approach.
Measurement-tool direction; specific assay or validation method is not disclosed in the supplied material.
Identified on the company site as an emerging measurement direction; YOXLO was also selected as a 2025 Semi-Finalist in the XPRIZE Healthspan competition.
